全文获取类型
| 收费全文 | 190894篇 |
| 免费 | 12692篇 |
| 国内免费 | 758篇 |
专业分类
| 耳鼻咽喉 | 2647篇 |
| 儿科学 | 5215篇 |
| 妇产科学 | 3609篇 |
| 基础医学 | 24715篇 |
| 口腔科学 | 3827篇 |
| 临床医学 | 18980篇 |
| 内科学 | 41051篇 |
| 皮肤病学 | 3019篇 |
| 神经病学 | 19124篇 |
| 特种医学 | 6809篇 |
| 外国民族医学 | 13篇 |
| 外科学 | 28426篇 |
| 综合类 | 2425篇 |
| 现状与发展 | 3篇 |
| 一般理论 | 206篇 |
| 预防医学 | 14186篇 |
| 眼科学 | 5102篇 |
| 药学 | 12232篇 |
| 中国医学 | 218篇 |
| 肿瘤学 | 12537篇 |
出版年
| 2023年 | 779篇 |
| 2022年 | 1384篇 |
| 2021年 | 3210篇 |
| 2020年 | 1950篇 |
| 2019年 | 3190篇 |
| 2018年 | 3765篇 |
| 2017年 | 2696篇 |
| 2016年 | 3171篇 |
| 2015年 | 3828篇 |
| 2014年 | 5559篇 |
| 2013年 | 8435篇 |
| 2012年 | 12313篇 |
| 2011年 | 13156篇 |
| 2010年 | 7370篇 |
| 2009年 | 6749篇 |
| 2008年 | 12334篇 |
| 2007年 | 13068篇 |
| 2006年 | 12543篇 |
| 2005年 | 12855篇 |
| 2004年 | 12103篇 |
| 2003年 | 11550篇 |
| 2002年 | 11066篇 |
| 2001年 | 1657篇 |
| 2000年 | 1277篇 |
| 1999年 | 1784篇 |
| 1998年 | 2435篇 |
| 1997年 | 2119篇 |
| 1996年 | 1778篇 |
| 1995年 | 1648篇 |
| 1994年 | 1484篇 |
| 1993年 | 1396篇 |
| 1992年 | 1134篇 |
| 1991年 | 1054篇 |
| 1990年 | 924篇 |
| 1989年 | 919篇 |
| 1988年 | 920篇 |
| 1987年 | 806篇 |
| 1986年 | 913篇 |
| 1985年 | 1008篇 |
| 1984年 | 1305篇 |
| 1983年 | 1225篇 |
| 1982年 | 1695篇 |
| 1981年 | 1554篇 |
| 1980年 | 1467篇 |
| 1979年 | 857篇 |
| 1978年 | 954篇 |
| 1977年 | 836篇 |
| 1976年 | 743篇 |
| 1975年 | 604篇 |
| 1974年 | 631篇 |
排序方式： 共有10000条查询结果，搜索用时 15 毫秒
31.
32.
Ramya C. Mosarla Muthiah Vaduganathan Arman Qamar Javid Moslehi Gregory Piazza Robert P. Giugliano 《Journal of the American College of Cardiology》2019,73(11):1336-1349
Patients with active cancer are at an increased risk of arterial and venous thromboembolism (VTE) and bleeding events. Historically, in patients with cancer, low molecular weight heparins have been preferred for treatment of VTE, whereas warfarin has been the standard anticoagulant for stroke prevention in patients with atrial fibrillation (AF). More recently, direct oral anticoagulants (DOACs) have been demonstrated to reduce the risk of venous and arterial thromboembolism in large randomized clinical trials of patients with VTE and AF, respectively, thus providing an attractive oral dosing option that does not require routine laboratory monitoring. In this review, we summarize available clinical trial data and guideline recommendations, and outline a practical approach to anticoagulation management of VTE and AF in cancer. 相似文献
33.
Stefaniuk Catherine M. Schlegelmilch June Meyerson Howard J. Harding Clifford V. Maitta Robert W. 《Journal of thrombosis and thrombolysis》2022,53(4):950-953
Journal of Thrombosis and Thrombolysis - Over the last few years data from our group have indicated that α-synuclein is important in development of immune cells as well as potentially... 相似文献
34.
35.
Stefan Scholz Florian Koerber Kinga Meszaros Rosa Maya Fassbender Bernhard Ultsch Robert R. Welte Wolfgang Greiner 《Vaccine》2019,37(12):1692-1701
Introduction
Invasive meningococcal disease (IMD) is a severe disease mainly affecting infants and young children. The most common serogroup causing IMD in Germany is the serogroup type B Neisseria meningitidis (MenB). The aim of the present study is to estimate the economic burden of MenB-related IMD in Germany.Method
A bottom-up, model-based costing approach has been used to calculate the diagnose- and age-specific yearly lifetime costs of a hypothetical cohort of MenB-related IMD cases. Direct costs contain the treatment cost for the acute phase of the disease, long-term sequelae, costs for rehabilitation, and public health response. Indirect costs are calculated for the human-capital approach and the friction-cost approach considering productivity losses of patients or parents for the acute phase and long-term sequelae. Publicly available databases from the Federal Statistical Office, the SOEP panel data set, literature, and expert opinion were used as data sources. All future costs beyond the reference year of 2015 were discounted at 3%.Results
The total costs for the hypothetical cohort (343 patients) from a societal perspective are €19.6 million (€57,100/IMD case) using the friction-cost approach and €58.8 million (€171,000/IMD case) using the human-capital approach. Direct costs amount to €18.6 million or €54,300 €/case. Sequelae are responsible for 81% of the direct costs/case.Discussion
The elevated costs/MenB-related IMD case reflect the severity of the disease. The total costs are sensitive to the productivity-loss estimation approach applied. MenB is an uncommon but severe disease; The costs/case reflect the severity of the disease and is within the same magnitude as for human papilloma virus infections. The available literature on sequelae is due to the uncommonness limited and heterogeneous. 相似文献36.
37.
38.
39.
40.